CAMP4 Therapeutics Is Maintained at Buy by Chardan Capital
Ratings actions from Benzinga: GMT) CAMP4 Therapeutics Price Target Cut to $6.00/Share From $6.50 by Chardan CapitalRatings actions from Benzinga
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.